Holen Sie sich die Stockscreener-App
7.75
4.45%
0.33
Handel nachbörslich:
7.75
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.42
Offen:
$7.49
24-Stunden-Volumen:
1.77M
Relative Volume:
0.98
Marktkapitalisierung:
$1.01B
Einnahmen:
$727.33M
Nettoeinkommen (Verlust:
$-108.03M
KGV:
-9.1825
EPS:
-0.844
Netto-Cashflow:
$-21.78M
1W Leistung:
-0.26%
1M Leistung:
-21.16%
6M Leistung:
-11.07%
1J Leistung:
-17.11%
1-Tages-Spanne:
$7.43
$7.89
1-Wochen-Bereich:
$7.065
$7.92
52-Wochen-Spanne:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
7.75 | 963.21M | 727.33M | -108.03M | -21.78M | -0.844 |
TMO
Thermo Fisher Scientific Inc
|
494.54 | 182.60B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
190.79 | 134.18B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
564.66 | 44.63B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.54 | 32.21B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
299.89 | 29.21B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
Geopolitics Watch: Will NeoGenomics Inc outperform the market in YEAR2026 Intraday Action & Community Consensus Trade Signals - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (NEO) Movement - news.stocktradersdaily.com
NeoGenomics Inc Stock: A Key Player in Cancer Diagnostics Amid Evolving Healthcare Demands - AD HOC NEWS
Loss Report: Should you buy the dip on NeoGenomics Inc2026 Summary & Consistent Return Investment Signals - baoquankhu1.vn
NeoGenomics Q2 2025 Earnings Preview - MSN
Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc. - nationaltoday.com
Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc. $NEO - MarketBeat
GRI Bio (NASDAQ:GRI) versus NeoGenomics (NASDAQ:NEO) Financial Contrast - Defense World
Vanguard files 13G/A: NeoGenomics (NEO) ownership shows 0 shares - stocktitan.net
Dip Buying: Whats the analyst consensus on NeoGenomics Inc2026 Selloffs & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
NeoGenomics, Inc. (NASDAQ: NEO) Q4 2025 earnings call transcript - MSN
NeoGenomics invites engagement on innovation in oncology at USCAP event - Traders Union
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
Aug PreEarnings: Is NeoGenomics Inc stock a falling knife or bargain buyTake Profit & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Retail: Is NeoGenomics Inc gaining market share2026 WrapUp & Fast Entry High Yield Tips - baoquankhu1.vn
Aug Chart Watch: Can NeoGenomics Inc deliver alpha2026 Institutional Moves & Smart Allocation Stock Reports - baoquankhu1.vn
NEO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NeoGenomics (NEO) launches RaDaR ST to capture share in $20B MRD market - msn.com
Discipline and Rules-Based Execution in NEO Response - news.stocktradersdaily.com
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Medicare Coverage for PanTracer LBx Liquid Biopsy Could Be A Game Changer For NeoGenomics (NEO) - simplywall.st
NeoGenomics (NEO) Launches RaDaR ST to Capture Share in $20B MRD Market - Insider Monkey
11 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey
NeoGenomics offers preview of booth presence at USCAP2026 - Traders Union
NeoGenomics Beats Investor Suit Over Growth Driver Claims - Law360
Will Medicare Coverage for PanTracer LBx Liquid Biopsy Shift NeoGenomics' (NEO) Diagnostic Narrative? - Yahoo Finance
NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges - marketsmojo.com
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - simplywall.st
NeoGenomics’ PanTracer LBx test receives Medicare coverage By Investing.com - Investing.com Australia
NEO NeoGenomics, Inc. Maintained: Cowen Buy, William Blair Market Perform Mar 2026 - Meyka
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance
NeoGenomics, Natera, and Amphastar Pharmaceuticals shares skyrocket, what you need to know - MSN
NeoGenomics Gets Dismissal of Cancer Test Misrepresentation Suit - Bloomberg Law News
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling - BioSpace
William Blair reiterates Market Perform on Neogenomics stock after Medicare coverage decision - Investing.com Australia
Neogenomics stock gets Medicare coverage for blood-based test By Investing.com - Investing.com Australia
Neogenomics stock gets MolDX reimbursement for cancer test By Investing.com - Investing.com Australia
Neogenomics stock gets Medicare coverage for blood-based test - Investing.com
NeoGenomics test gains Medicare coverage for cancer care - Gulfshore Business
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biop - pharmiweb.com
Neogenomics stock gets MolDX reimbursement for cancer test - Investing.com
Neogenomics IncPantracer Lbx Test Receives Medicare Coverage Under CMS Moldx Program - TradingView
NeoGenomics’ PanTracer LBx test receives Medicare coverage - Investing.com
NeoGenomics, Inc. $NEO Stock Position Increased by First Light Asset Management LLC - MarketBeat
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):